Quarterly report · Q3
2269.TEDINET S100SSKZ
Period2023-04-01 → 2023-12-31
Filed2024-02-09
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥833.0bn | 2023-04-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥1.06T | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥798.1bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | ¥69.7bn | 2023-04-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥64.7bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | ¥68.3bn | 2023-04-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥74.2bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥66.4bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥74.0bn | 2023-04-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥69.0bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥44.9bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥69.4bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥47.3bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥48.4bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥49.6bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥1.24T | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥1.14T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.21T | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥442.5bn | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥384.9bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥793.5bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥751.3bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥748.1bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥92.3bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥63.5bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥88.5bn | at 2023-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥60.9bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥85.9bn | at 2022-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥64.9bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥64.5bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥85.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥36.7bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥29.4bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥36.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥41.8bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥10.6bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥54.7bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥21.3bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥161.13 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥61 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥247.39 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥168.12 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥49.57 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 60.8% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.7% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.2% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-12-31 | −¥579m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-12-31 | −¥579m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-12-31 | −¥1.7bn |
| jpcrp040300-q3r_E21902-000Foodreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥679.5bn |
| jpcrp040300-q3r_E21902-000Foodreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥678.9bn |
| jpcrp040300-q3r_E21902-000Foodreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥563m |
| jpcrp040300-q3r_E21902-000Foodreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥48.7bn |
| jpcrp040300-q3r_E21902-000Pharmaceuticalreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥154.1bn |
| jpcrp040300-q3r_E21902-000Pharmaceuticalreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥154.1bn |
| jpcrp040300-q3r_E21902-000Pharmaceuticalreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥16m |
| jpcrp040300-q3r_E21902-000Pharmaceuticalreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥22.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-12-31 | ¥833.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-12-31 | ¥833.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥579m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-12-31 | ¥71.5bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥557m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥557m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥1.4bn |
| jpcrp040300-q3r_E21902-000Foodreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥649.9bn |
| jpcrp040300-q3r_E21902-000Foodreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥649.4bn |
| jpcrp040300-q3r_E21902-000Foodreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥542m |
| jpcrp040300-q3r_E21902-000Foodreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥45.1bn |
| jpcrp040300-q3r_E21902-000Pharmaceuticalreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥148.7bn |
| jpcrp040300-q3r_E21902-000Pharmaceuticalreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥148.7bn |
| jpcrp040300-q3r_E21902-000Pharmaceuticalreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥14m |
| jpcrp040300-q3r_E21902-000Pharmaceuticalreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥21.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-12-31 | ¥798.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-12-31 | ¥798.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥557m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-12-31 | ¥66.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 514
| Item | Context | Value | Unit |
|---|---|---|---|
| Net cash provided by used in investment activities | CurrentYTDDuration | -29422000000 | JPY |
| Net increase decrease in short term loans payable fin cf | Prior1YTDDuration | 35393000000 | JPY |
| Net increase decrease in short term loans payable fin cf | CurrentYTDDuration | 9684000000 | JPY |
| Increase decrease in commercial papers fin cf | Prior1YTDDuration | 25000000000 | JPY |
| Increase decrease in commercial papers fin cf | CurrentYTDDuration | 20000000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -3093000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -3000000000 | JPY |
| Redemption of bonds fin cf | Prior1YTDDuration | － | JPY |
| Redemption of bonds fin cf | CurrentYTDDuration | -10000000000 | JPY |
| Decrease increase in treasury stock fin cf | Prior1YTDDuration | -9496000000 | JPY |
| Decrease increase in treasury stock fin cf | CurrentYTDDuration | 1060000000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -24541000000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -26362000000 | JPY |
| Dividends paid to non controlling interests fin cf | Prior1YTDDuration | -1430000000 | JPY |
| Dividends paid to non controlling interests fin cf | CurrentYTDDuration | -676000000 | JPY |
| Other net fin cf | Prior1YTDDuration | -532000000 | JPY |
| Other net fin cf | CurrentYTDDuration | -1261000000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | 21300000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -10555000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 4837000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | 3011000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 21035000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 27571000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 64872000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 60939000000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 85908000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 88510000000 | JPY |
| Discounted trade notes receivable | Prior1YearInstant | 2000000 | JPY |
| Discounted trade notes receivable | CurrentQuarterInstant | － | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q3r_E21902-000FoodReportableSegmentsMember | 649397000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q3r_E21902-000PharmaceuticalReportableSegmentsMember | 148686000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 798083000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 798083000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E21902-000FoodReportableSegmentsMember | 542000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E21902-000PharmaceuticalReportableSegmentsMember | 14000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 557000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -557000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E21902-000FoodReportableSegmentsMember | 649939000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E21902-000PharmaceuticalReportableSegmentsMember | 148701000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 798640000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -557000000 | JPY |
| Net sales | Prior1YTDDuration | 798083000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E21902-000FoodReportableSegmentsMember | 45125000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E21902-000PharmaceuticalReportableSegmentsMember | 21037000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 66163000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -1424000000 | JPY |
| Operating income | Prior1YTDDuration | 64739000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E21902-000FoodReportableSegmentsMember | 678932000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |